Market Insights, 16 November 2026

Key developments, a cross-asset dashboard and the events calendar for 16 to 20 November, from the TFOS trading desk.

Market Insights, 9 November 2026

Key developments, a cross-asset dashboard and the events calendar for 9 to 13 November, from the TFOS trading desk.

Market Insights, 2 November 2026

Key developments, a cross-asset dashboard and the events calendar for 2 to 6 November, from the TFOS trading desk.

IPO Review: four October listings, two well above their offer price

City Therapeutics and Lycia trade well above their IPO prices, TRex Bio and Iambic below: price action and catalysts.

Market Insights, 26 October 2026

Key developments, a cross-asset dashboard and the events calendar for 26 to 30 October, from the TFOS trading desk.

Market Insights, 19 October 2026

Key developments, a cross-asset dashboard and the events calendar for 20 to 23 October, from the TFOS trading desk.

IPO Review: three September listings, one above its offer price

Electra Therapeutics and Orion180 trade below their IPO prices, ADARx Pharmaceuticals holds above its own: price action and catalysts.

Tokenization: a review for South African investors

What tokenized assets are, how they are regulated, and what they mean for adviser and HNW portfolios. 44 pages.

The market has its say: how July's IPOs are performing

Post-IPO coverage of Csquare, Standard Nuclear and Scribe Therapeutics: three July listings, three very different receptions.

Friday IPO Review: six listings, one nearly doubled

APMD up ~98% from its IPO price, Lyntris below its offer: the businesses, catalysts and risks behind six recent listings.

Marketing communication, not independent investment research and not financial advice. Past performance is not a guide to future results. Turlov Family Office Securities (Pty) Ltd is an authorised FSP (52874).